IL133397A - Pharmaceutical compositions for oral administration comprising an active substance and a cyclodextrin - Google Patents

Pharmaceutical compositions for oral administration comprising an active substance and a cyclodextrin

Info

Publication number
IL133397A
IL133397A IL13339798A IL13339798A IL133397A IL 133397 A IL133397 A IL 133397A IL 13339798 A IL13339798 A IL 13339798A IL 13339798 A IL13339798 A IL 13339798A IL 133397 A IL133397 A IL 133397A
Authority
IL
Israel
Prior art keywords
cyclodextrin
pharmaceutical compositions
oral administration
active substance
family
Prior art date
Application number
IL13339798A
Other languages
English (en)
Other versions
IL133397A0 (en
Original Assignee
Ucb Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3890611&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL133397(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Sa filed Critical Ucb Sa
Publication of IL133397A0 publication Critical patent/IL133397A0/xx
Publication of IL133397A publication Critical patent/IL133397A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL13339798A 1997-07-03 1998-07-02 Pharmaceutical compositions for oral administration comprising an active substance and a cyclodextrin IL133397A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BE9700572A BE1011251A3 (fr) 1997-07-03 1997-07-03 Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine.
PCT/BE1998/000100 WO1999001133A1 (fr) 1997-07-03 1998-07-02 Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine

Publications (2)

Publication Number Publication Date
IL133397A0 IL133397A0 (en) 2001-04-30
IL133397A true IL133397A (en) 2005-07-25

Family

ID=3890611

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13339798A IL133397A (en) 1997-07-03 1998-07-02 Pharmaceutical compositions for oral administration comprising an active substance and a cyclodextrin

Country Status (20)

Country Link
US (1) US6455533B1 (de)
EP (1) EP0994710B2 (de)
JP (2) JP2002508773A (de)
KR (1) KR100551510B1 (de)
CN (1) CN1150900C (de)
AT (1) ATE224717T1 (de)
AU (1) AU727140B2 (de)
BE (1) BE1011251A3 (de)
BR (1) BR9810495A (de)
CA (1) CA2294783C (de)
DE (1) DE69808297T3 (de)
DK (1) DK0994710T4 (de)
ES (1) ES2184293T5 (de)
ID (1) ID23806A (de)
IL (1) IL133397A (de)
NZ (1) NZ501820A (de)
PL (1) PL192348B1 (de)
PT (1) PT994710E (de)
RU (1) RU2192863C2 (de)
WO (1) WO1999001133A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0028575D0 (en) * 2000-11-23 2001-01-10 Elan Corp Plc Oral pharmaceutical compositions containing cyclodextrins
BR0206979A (pt) * 2001-02-05 2004-04-20 Scherer Technologies Inc R P Métodos e composições para reduzir o paladar de agentes farmaceuticamente ativos
EP1467715B1 (de) * 2002-01-15 2010-11-03 Ucb Farchim S.A. Formulierungen zur oralen verabreichung von wirkstoffen
CA2481025A1 (en) * 2002-04-04 2003-10-16 Tanya Havlir Palatable chewable tablet
WO2006011051A1 (en) * 2004-07-22 2006-02-02 Pfizer Products Inc. Taste masking formulation comprising the drug in a dissolution-retarded form and/or cyclodextrin in a dissolution-enhanced form
US20060147518A1 (en) * 2004-12-30 2006-07-06 Pierre Fabre Medicament Stable solid dispersion of a derivative of vinca alkaloid and process for manufacturing it
US20060198885A1 (en) * 2005-02-22 2006-09-07 Sun Pharmaceutical Industries Ltd. Oral pharmaceutical composition
US20070086974A1 (en) * 2005-10-06 2007-04-19 Gawande Rahul S Cetirizine compositions
US20090269393A1 (en) * 2006-06-12 2009-10-29 Jubliant Organosys Limited Chewable Bilayer Tablet Formulation
JP2008143807A (ja) * 2006-12-07 2008-06-26 Sato Pharmaceutical Co Ltd 感冒薬カプセル剤及びその製造方法
DK2178521T3 (da) * 2007-07-11 2014-04-28 Fertin Pharma As Stabilt medicinsk tyggegummi omfattende cyclodextrin-inklusionskompleks
EP2550967A1 (de) * 2007-07-11 2013-01-30 Fertin Pharma A/S Komprimierte Kaugummitablette mit Geschmacksmaskierungsmittel
WO2009054432A1 (ja) * 2007-10-26 2009-04-30 Daiichi Sankyo Company, Limited 口腔内速崩壊性医薬組成物およびその製造方法
US8138192B2 (en) * 2007-10-31 2012-03-20 Genebiology, Inc. Injectable meclizine formulations and methods
WO2009061465A1 (en) 2007-11-06 2009-05-14 Teva Pharmaceutical Industries Ltd. Chewable formulations
CN102143737A (zh) * 2008-09-05 2011-08-03 麦克内尔-Ppc股份有限公司 制备西替利嗪片剂的方法
BR112012003592B8 (pt) 2009-08-19 2021-05-25 Eisai R&D Man Co Ltd composição farmacêutica contendo derivado de quinolina
WO2011110939A2 (en) * 2010-03-11 2011-09-15 Rubicon Research Private Limited Pharmaceutical compositions of substituted benzhydrylpiperazines
CN103037839A (zh) * 2010-06-04 2013-04-10 全球药物科技有限公司 含有矫味剂的口服美其敏水性制剂
CN101905027A (zh) * 2010-07-27 2010-12-08 北京华禧联合科技发展有限公司 含米格列奈钙和环糊精的口服药用组合物
PH12013500477A1 (en) 2010-09-13 2018-01-17 Bev Rx Inc Aqueous drug delivery system comprising off-flavor masking agent
WO2012166899A2 (en) 2011-06-03 2012-12-06 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
RU2589833C2 (ru) * 2013-12-12 2016-07-10 Общество С Ограниченной Ответственностью "Фарма Старт" Твердая лекарственная форма препарата седативного и снотворного действия
CN111632023A (zh) * 2014-03-27 2020-09-08 Ucb法奇姆股份有限公司 包含左西替利嗪的药物组合物
CA2957005C (en) 2014-08-28 2021-10-12 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
SG11201706630UA (en) 2015-02-25 2017-09-28 Eisai R&D Man Co Ltd Method for suppressing bitterness of quinoline derivative
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
JP6553726B2 (ja) 2015-08-20 2019-07-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
BR112019023064A2 (pt) 2017-05-16 2020-06-09 Eisai R&D Man Co Ltd tratamento de carcinoma hepatocelular
KR102110304B1 (ko) * 2017-06-30 2020-05-14 한미약품 주식회사 레보세티리진 및 몬테루카스트를 포함하는 안정성 및 복약순응도가 향상된 복합 츄어블정 및 그 제조방법
JP7703137B2 (ja) * 2020-02-03 2025-07-07 ケンビュー・ブランズ・エルエルシー セチリジンを含む単層チュアブル錠剤
US20230414597A1 (en) 2020-11-18 2023-12-28 BioPharma Synergies, S. L. Orodispersible powder composition comprising an antihistamine compound

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI75816C (fi) 1981-02-06 1988-08-08 Ucb Sa Foerfarande foer framstaellning av terapeutiskt aktiv 2-/4-(difenylmetyl)-1-piperazinyl/-aettiksyror eller dess amid.
JPS58177949A (ja) * 1982-04-12 1983-10-18 Takeda Chem Ind Ltd ランカシジン群抗生物質包接化合物
JPS60204712A (ja) * 1984-03-29 1985-10-16 Ss Pharmaceut Co Ltd 塩酸メクリジンの安定化液状組成物
JPS63243031A (ja) † 1987-03-28 1988-10-07 Tokyo Tanabe Co Ltd 胆汁酸の固形製剤
FR2647343B1 (fr) * 1989-05-24 1994-05-06 Rhone Poulenc Sante Nouvelle forme pharmaceutique poreuse et sa preparation
US5206025A (en) * 1989-05-24 1993-04-27 Rhone-Poulenc Sante Porous pharmaceutical form and its preparation
JPH08501561A (ja) † 1992-09-24 1996-02-20 セプラコア，インコーポレイテッド （−）セチリジンを用いたアレルギー疾患の治療のための組成物
TW401300B (en) * 1992-12-25 2000-08-11 Senju Pharma Co Antiallergic composition for ophthalmic or nasal use
HU217298B (hu) * 1993-12-01 1999-12-28 Byk Gulden Lomberg Chemische Fabrik Gmbh. (Helyettesített amino)-alkil-amino-piridil-metil-tio-benzimidazol- és -imidazo [5,4-b]piridin-származékok, előállításuk és alkalmazásuk, valamint a vegyületeket tartalmazó gyógyászati készítmények
US5866179A (en) 1996-05-03 1999-02-02 Avant-Garde Technologies & Products S.A. Medicated chewing gum and a process for preparation thereof
GB0028575D0 (en) * 2000-11-23 2001-01-10 Elan Corp Plc Oral pharmaceutical compositions containing cyclodextrins
WO2006011051A1 (en) * 2004-07-22 2006-02-02 Pfizer Products Inc. Taste masking formulation comprising the drug in a dissolution-retarded form and/or cyclodextrin in a dissolution-enhanced form

Also Published As

Publication number Publication date
DK0994710T4 (da) 2005-10-17
AU727140B2 (en) 2000-12-07
KR100551510B1 (ko) 2006-02-13
US6455533B1 (en) 2002-09-24
DE69808297T3 (de) 2006-01-19
WO1999001133A1 (fr) 1999-01-14
EP0994710B2 (de) 2005-09-21
ID23806A (id) 2000-05-11
NZ501820A (en) 2000-10-27
JP2007091760A (ja) 2007-04-12
DE69808297T2 (de) 2003-04-17
PT994710E (pt) 2003-02-28
DE69808297D1 (de) 2002-10-31
BR9810495A (pt) 2000-09-12
HK1029060A1 (en) 2001-03-23
RU2192863C2 (ru) 2002-11-20
EP0994710A1 (de) 2000-04-26
CN1150900C (zh) 2004-05-26
DK0994710T3 (da) 2003-01-20
CA2294783A1 (fr) 1999-01-14
KR20010014398A (ko) 2001-02-26
ES2184293T3 (es) 2003-04-01
BE1011251A3 (fr) 1999-06-01
US20020032217A1 (en) 2002-03-14
CN1261799A (zh) 2000-08-02
CA2294783C (fr) 2006-11-14
PL337794A1 (en) 2000-09-11
ATE224717T1 (de) 2002-10-15
PL192348B1 (pl) 2006-10-31
ES2184293T5 (es) 2006-01-16
EP0994710B1 (de) 2002-09-25
IL133397A0 (en) 2001-04-30
AU8201598A (en) 1999-01-25
JP2002508773A (ja) 2002-03-19

Similar Documents

Publication Publication Date Title
IL133397A0 (en) Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin
IL136285A0 (en) Pharmaceutical compositions containing an acid-labile active component
BG106030A (en) Pharmaceutical composition
MY118151A (en) Pharmaceutical formulations containing voriconazole.
PL347671A1 (en) Compounds and compositions for delivering active agents
BR0015188A (pt) Composições farmacêuticas
GEP20053473B (en) High Potency Dihydroergotamine Compositions
AU2274201A (en) Compounds and compositions for delivering active agents
AU2845599A (en) Pharmaceutical compositions and their use
IL141762A0 (en) New oral formulations
FI973828A0 (fi) Yhdisteitä ja koostumuksia aktiivisten aineiden annostelemiseksi
ZA200308221B (en) Pharmaceutical compositions for oral and topical administration.
ATE287264T1 (de) Oral anzuwendende buprenorphinhaltige arzneimittel
PL346764A1 (en) New oral formulation for 5-ht4
PL348419A1 (en) Sustained-release pharmaceutical preparation containing tilidine mesylate as active ingredient
CA2348474A1 (en) Pharmaceutically active composition and dispensing device
AU3580995A (en) Derivatives of carbohydrates and compositions containing them
EP1273301A3 (de) Pharmazeutische Zubereitungen, Wirkstoffe enthaltend, die sich für unerlaubte Verabreichung bieten
GEP20043377B (en) Pharmaceutical Complex
MD1473F2 (en) Antiherpetic remedy
AU2502301A (en) Medicament and combination of compatible medicaments
IL142112A0 (en) Pharmaceutical compositions based on alpha-cyclodextrin for the oral administration of lh-rh analogues
TW429144B (en) The pharmaceutical composition comprising the Con.A-Maltose complex and vehicle for oral use
ECSP941154A (es) Procedimiento para preparar una composicion farmaceutica a base de ciclosporina
MY152490A (en) New oral formulation

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees